Tempus and Recursion swap up to $84 million in optional fees for $42 million committed
The data license now runs through November 2029, and Tempus also licenses Recursion's TxFM RNA model.
Tempus AI said on September 21, 2026, that it had extended its data license agreement with Recursion Pharmaceuticals through November 2029.
Per the release, the parties replaced discretionary license fees potentially totaling $84 million over the next two years with committed payments totaling $42 million over the next three years.
Tempus also entered a new agreement to license Recursion's RNA foundation model, TxFM, on a non-exclusive, worldwide basis under a separate agreement.
Why it matters: this is a rare public look at how a data license gets repriced. The headline potential fell by half, but the money became committed rather than optional.
Sources
Spotted an error? See our corrections policy.
Related
- PayoutsPolicy
Scale AI's proposed $12.5 million California wage settlement names Outlier; Mercor faces a misclassification suit in Texas
The McKinney settlement administrator had not posted a final approval when we checked on Nov. 17. In White v. Mercor, an amended motion to compel arbitration is pending.
- PayoutsLabs
What AI training platforms post for pay: Mercor and micro1 list hourly rates, Outlier lists none
A snapshot of three official pages on Nov. 17, 2026. These are posted rates for listed roles, not what workers actually earn.
- DealsLabsPolicy
Spirit Airlines data-sale hearing is Tuesday as Google's $10 million bid awaits court approval
A bankruptcy judge in White Plains takes up the sale of Spirit's de-identified business data on Nov. 17. Mercor is the $7.5 million alternate bidder.
- DealsLabs
Court approves Character.AI bidding procedures: bids due Nov. 24, auction Dec. 1
Disney Worldwide Services is the stalking-horse counterparty. The Next Web, citing the filing, reported that the license excludes user data and training data.